Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Blockbuster dreams for Pfizer's CDK inhibitor

Nature Biotechnology volume 31, page 187 (2013)Cite this article

Subjects

Some analysts believe that the drug has multibillion dollar sales potential, with Mark Schoenebaum at ISI Group, New York, stating that it has blockbuster potential in ER-positive breast cancer alone, given the strength of the data and large patient population. However, analyst Tony Butler at Barclays Capital in New York cautiously says that he is awaiting confirmation that it improves overall survival.

The palbociclib data bode especially well for the other CDK4/6 inhibitors in earlier clinical development, according to researchers. These include Lilly's LY2835219, which will soon begin phase 2 development in mantle cell lymphoma (MCL), and Novartis' LEE011. The drugs inhibit phosphorylation of the retinoblastoma protein in the early G1 phase of the cell cycle, blocking progression to S phase, where DNA is replicated.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Freehold, New Jersey

    Malini Guha

Authors
  1. Malini Guha
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guha, M. Blockbuster dreams for Pfizer's CDK inhibitor. Nat Biotechnol 31, 187 (2013). https://doi.org/10.1038/nbt0313-187a

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0313-187a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer